Pharmacogenomic testing could help reduce adverse drug reactions in the UK
Unlocking the Power of Pharmacogenomics Recent studies at Queen Mary University of London have highlighted the immense potential of pharmacogenomics (PGx)—the study of how genes affect a person’s response to drugs—in reducing adverse drug reactions (ADRs). The research shows that 9% of all ADRs in the UK could be linked to genetic factors, with 75% … Read more